Surv.m-CRA-1
Oncology (unspecified solid tumors)
Phase 1Licensed to Nippon Zoki Pharmaceutical
Key Facts
Indication
Oncology (unspecified solid tumors)
Phase
Phase 1
Status
Licensed to Nippon Zoki Pharmaceutical
Company
About Surv Biopharma
A Kagoshima University spin-out developing survivin-promoter-driven oncolytic viruses and gene therapy vectors for oncology and metabolic diseases.
View full company profileTherapeutic Areas
Other Oncology (unspecified solid tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| RPT1G | Remedy Plan Therapeutics | Phase 1 |